PROBIOTIX HEALTH LS-05 (X90) - Total Assets

Latest as of June 2025: €2.38 Million EUR ≈ $2.78 Million USD

Based on the latest financial reports, PROBIOTIX HEALTH LS-05 (X90) holds total assets worth €2.38 Million EUR (≈ $2.78 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

PROBIOTIX HEALTH LS-05 - Total Assets Trend (2022–2024)

This chart illustrates how PROBIOTIX HEALTH LS-05's total assets have evolved over time, based on quarterly financial data. Also see PROBIOTIX HEALTH LS-05 market cap and net worth for the company's overall valuation and market capitalisation.

PROBIOTIX HEALTH LS-05 - Asset Composition Analysis

Current Asset Composition (December 2024)

PROBIOTIX HEALTH LS-05's total assets of €2.38 Million consist of 88.8% current assets and 11.2% non-current assets. Review PROBIOTIX HEALTH LS-05 (X90) total liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 75.6%
Accounts Receivable €141.00K 6.5%
Inventory €31.00K 1.4%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €239.00K 11.0%
Goodwill €0.00 0.0%

Asset Composition Trend (2022–2024)

This chart illustrates how PROBIOTIX HEALTH LS-05's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See X90 live share price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: PROBIOTIX HEALTH LS-05's current assets represent 88.8% of total assets in 2024, an increase from 86.5% in 2022.
  • Cash Position: Cash and equivalents constituted 75.6% of total assets in 2024, up from 65.8% in 2022.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 13.0% in 2022.
  • Asset Diversification: The largest asset category is intangible assets at 11.0% of total assets.

PROBIOTIX HEALTH LS-05 Competitors by Total Assets

Key competitors of PROBIOTIX HEALTH LS-05 based on total assets are shown below.

Company Country Total Assets
CSL Ltd
AU:CSL
Australia AU$39.54 Billion
Vaxcyte Inc
NASDAQ:PCVX
USA $3.14 Billion
Bachem Holding AG
SW:BANB
Switzerland CHF2.11 Billion
Definium Therapeutics, Inc.
NASDAQ:DFTX
USA $1.11 Billion
Chongqing Zhifei Bio Products
SHE:300122
China CN¥29.09 Billion
HLB Co. Ltd
KQ:028300
Korea ₩925.44 Billion
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
China CN¥6.82 Billion
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
China CN¥3.16 Billion

PROBIOTIX HEALTH LS-05 - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.02 3.06 3.06
Quick Ratio 3.99 2.88 2.88
Cash Ratio 0.00 0.00 0.00
Working Capital €1.62 Million €1.07 Million €1.07 Million

PROBIOTIX HEALTH LS-05 - Advanced Valuation Insights

This section examines the relationship between PROBIOTIX HEALTH LS-05's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.62
Latest Market Cap to Assets Ratio 6.78
Asset Growth Rate (YoY) 0.2%
Total Assets €2.18 Million
Market Capitalization $14.76 Million USD

Valuation Analysis

Premium Asset Valuation: The market values PROBIOTIX HEALTH LS-05's assets at a significant premium (6.78x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: PROBIOTIX HEALTH LS-05's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for PROBIOTIX HEALTH LS-05 (2022–2024)

The table below shows the annual total assets of PROBIOTIX HEALTH LS-05 from 2022 to 2024.

Year Total Assets Change
2024-12-31 €2.18 Million
≈ $2.55 Million
+0.23%
2023-12-31 €2.17 Million
≈ $2.54 Million
-7.26%
2022-12-31 €2.34 Million
≈ $2.74 Million
--

About PROBIOTIX HEALTH LS-05

F:X90 Germany Biotechnology
Market Cap
$16.46 Million
€14.08 Million EUR
Market Cap Rank
#26118 Global
#2243 in Germany
Share Price
€0.09
Change (1 day)
+0.00%
52-Week Range
€0.05 - €0.10
All Time High
€24.53
About

ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more